利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.028 秒)

    Human chemotactic cytokine
    2.
    发明授权
    Human chemotactic cytokine 失效
    人类趋化细胞因子

    公开(公告)号：US07285620B2

    公开(公告)日：2007-10-23

    申请号：US11133140

    申请日：2005-05-19

    申请人： Paul D. Ponath ,  Shixin Qin ,  Douglas J. Ringler ,  Walter Newman ,  Charles Mackay

    发明人： Paul D. Ponath ,  Shixin Qin ,  Douglas J. Ringler ,  Walter Newman ,  Charles Mackay

    IPC分类号： C07K14/52 ,  C12N15/63

    CPC分类号： C07K16/24 ,  A61K38/00 ,  A61K47/642 ,  C07K14/523 ,  C07K14/7158 ,  C07K2317/76 ,  C07K2319/00

    摘要： The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.

    摘要翻译： 本发明涉及编码人类趋化性细胞因子（命名为人类嗜酸细胞活化趋化因子）的分离和/或重组核酸，以及包含合成多肽的分离和/或重组人类嗜酸细胞活化趋化因子蛋白或多肽。 本发明还涉及重组核酸构建体，其包含编码人类嗜酸细胞活化趋化因子，其部分或变体的核酸; 包含可用于生产重组人类嗜酸性粒细胞趋化因子的这种构建体的宿主细胞; 以及可用于体外方法，诊断和/或治疗的与人嗜酸细胞活化趋化因子反应的抗体。 还提供了使用嗜酸细胞活化趋化因子蛋白质的方法，例如将嗜酸性粒细胞募集到特定部位或用于治疗过敏性病症。 人类嗜酸性粒细胞趋化因子可用于鉴定可用于选择性调节白细胞功能，炎性和自身免疫疾病或感染的人类嗜酸细胞活化趋化因子的抑制剂（例如拮抗剂）或启动子（激动剂）。

    C-C chemokine receptor 3 proteins
    4.
    发明申请
    C-C chemokine receptor 3 proteins 审中-公开
    C-C趋化因子受体3蛋白

    公开(公告)号：US20090068188A1

    公开(公告)日：2009-03-12

    申请号：US12218102

    申请日：2008-07-11

    申请人： Craig J. Gerard ,  Norma P. Gerard ,  Charles R. Mackav ,  Paul D. Ponath ,  Theodore W. Post ,  Shixin Qin

    发明人： Craig J. Gerard ,  Norma P. Gerard ,  Charles R. Mackav ,  Paul D. Ponath ,  Theodore W. Post ,  Shixin Qin

    IPC分类号： A61K39/395 ,  A61P29/00

    CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K38/00 ,  A61K47/642 ,  C07K14/7158 ,  C07K2317/76 ,  C07K2319/00 ,  C12N2799/026

    摘要： The present invention relates to methods of inhibiting a mammalian C-C chemokine receptor 3 protein (CCR3). The invention further relates to methods of treating an inflammatory disease or condition. Administration of a compound which inhibits or promotes CCR3 function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.

    摘要翻译： 本发明涉及抑制哺乳动物C-C趋化因子受体3蛋白（CCR3）的方法。 本发明还涉及治疗炎性疾病或病症的方法。 向需要治疗的个体抑制或促进CCR3功能的化合物的施用提供了选择性调节白细胞功能的新方法，其可用于多种炎性和自身免疫性疾病或用于治疗感染。 作为白细胞如嗜酸性粒细胞和淋巴细胞中存在的主要白细胞趋化因子受体，该受体是药物筛选和设计的关键目标。

    Humanized immunoglubulin reactive with alph4beta7 integrin
    5.
    发明申请
    Humanized immunoglubulin reactive with alph4beta7 integrin 审中-公开
    人源化免疫球蛋白与alph4beta7整合素反应

    公开(公告)号：US20090011464A1

    公开(公告)日：2009-01-08

    申请号：US12214304

    申请日：2008-06-18

    申请人： Paul D. Ponath ,  Douglas J. Ringler ,  S. Tarran Jones ,  Walter Newman ,  Jose Saldanha ,  Mary M. Bendig

    发明人： Paul D. Ponath ,  Douglas J. Ringler ,  S. Tarran Jones ,  Walter Newman ,  Jose Saldanha ,  Mary M. Bendig

    IPC分类号： C12P21/00 ,  C07H21/00 ,  C12N15/63 ,  C12N5/00

    摘要： The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for α4β7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for α4β7 integrin.

    摘要翻译： 本发明涉及编码对α4β7整联蛋白具有结合特异性，编码人源化免疫球蛋白重链的分离的核酸和编码具有α4β7整联蛋白的结合特异性的人源化轻链的分离的核酸的分离的核酸。 本发明还涉及包含编码具有对α4β7具有结合特异性的人源化免疫球蛋白或其抗原结合片段的核苷酸序列的表达载体和宿主细胞。 本发明还涉及制备对α4β7整联蛋白具有结合特异性的人源化免疫球蛋白，人源化免疫球蛋白重链和人源化免疫球蛋白轻链的方法。

    Antibodies to human eotaxin
    6.
    发明授权
    Antibodies to human eotaxin 失效
    人类嗜酸性粒细胞趋化因子的抗体

    公开(公告)号：US07423129B2

    公开(公告)日：2008-09-09

    申请号：US11900700

    申请日：2007-09-13

    申请人： Paul D. Ponath ,  Shixin Qin ,  Douglas J. Ringler ,  Walter Newman ,  Charles Mackay

    发明人： Paul D. Ponath ,  Shixin Qin ,  Douglas J. Ringler ,  Walter Newman ,  Charles Mackay

    IPC分类号： C07K16/24 ,  C12N5/12

    CPC分类号： C07K16/24 ,  A61K38/00 ,  A61K47/642 ,  C07K14/523 ,  C07K14/7158 ,  C07K2317/76 ,  C07K2319/00

    摘要： The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.

    摘要翻译： 本发明涉及编码人类趋化性细胞因子（命名为人类嗜酸细胞活化趋化因子）的分离和/或重组核酸，以及包含合成多肽的分离和/或重组人类嗜酸细胞活化趋化因子蛋白或多肽。 本发明还涉及重组核酸构建体，其包含编码人类嗜酸细胞活化趋化因子，其部分或变体的核酸; 包含可用于生产重组人类嗜酸性粒细胞趋化因子的这种构建体的宿主细胞; 以及可用于体外方法，诊断和/或治疗的与人嗜酸细胞活化趋化因子反应的抗体。 还提供了使用嗜酸细胞活化趋化因子蛋白质的方法，例如将嗜酸性粒细胞募集到特定部位或用于治疗过敏性病症。 人类嗜酸性粒细胞趋化因子可用于鉴定可用于选择性调节白细胞功能，炎性和自身免疫疾病或感染的人类嗜酸细胞活化趋化因子的抑制剂（例如拮抗剂）或启动子（激动剂）。

    Antibodies to C-C chemokine Receptor 3 Protein
    7.
    发明授权
    Antibodies to C-C chemokine Receptor 3 Protein 失效
    C-C趋化因子受体3蛋白的抗体

    公开(公告)号：US07012133B1

    公开(公告)日：2006-03-14

    申请号：US08963656

    申请日：1997-11-03

    申请人： Craig J. Gerard ,  Norma P. Gerard ,  Charles R. Mackay ,  Paul D. Ponath ,  Theodore W. Post ,  Shixin Qin

    发明人： Craig J. Gerard ,  Norma P. Gerard ,  Charles R. Mackay ,  Paul D. Ponath ,  Theodore W. Post ,  Shixin Qin

    IPC分类号： C07K16/00 ,  C12N15/63 ,  C12N15/00

    CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K38/00 ,  A61K47/642 ,  C07K14/7158 ,  C07K2317/76 ,  C07K2319/00 ,  C12N2799/026

    摘要： The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C—C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof; to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function. Administration of a compound which inhibits or promotes receptor function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.

    摘要翻译： 本发明涉及编码称为CC趋化因子受体3（CKR-3）或Eos L2的哺乳动物（例如，人）受体蛋白以及本文称为分离的重组体的蛋白质或多肽的分离和/或重组核酸 哺乳动物CKR-3受体。 本发明还涉及重组核酸构建体，其包含编码本发明的受体蛋白或其部分的核酸; 包含可用于产生重组CKR-3受体或多肽的包含此类构建体的宿主细胞; 以及与受体反应的抗体，其可用于研究和诊断应用。 还提供了使用核酸，蛋白质和宿主细胞来鉴定受体功能的配体，抑制剂（例如拮抗剂）或启动子（激动剂）的方法。 给予需要治疗的个体抑制或促进受体功能的化合物的施用提供了选择性调节白细胞功能的新方法，其可用于多种炎性和自身免疫疾病或用于治疗感染。 作为白细胞如嗜酸性粒细胞和淋巴细胞中存在的主要白细胞趋化因子受体，该受体是药物筛选和设计的关键目标。

    Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
    9.
    发明授权
    Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function 有权
    抗GPR-9-6抗体和鉴定调节GPR-9-6功能的药物的方法

    公开(公告)号：US06329159B1

    公开(公告)日：2001-12-11

    申请号：US09266464

    申请日：1999-03-11

    申请人： David P. Andrew ,  Brian A. Zabel ,  Paul D. Ponath

    发明人： David P. Andrew ,  Brian A. Zabel ,  Paul D. Ponath

    IPC分类号： A61K39395

    CPC分类号： C07K16/2866 ,  C07K16/24 ,  C07K2317/76 ,  Y10S435/81 ,  Y10S435/975

    摘要： The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.

    摘要翻译： 本发明涉及与CC趋化因子受体GPR-9-6结合并阻断配体（例如TECK）与受体结合的抗体或其抗原结合片段。 本发明还涉及鉴定可以结合GPR-9-6并抑制配体（例如TECK）结合和/或调节GPR-9-6的功能的试剂（分子，化合物）的方法。 本发明还涉及调节GPR-9-6的功能的方法，以及通过本发明的方法鉴定的抗体，抗原结合片段和试剂在研究，治疗，预防和诊断方法中的用途。

    Human chemotactic cytokine
    10.
    发明申请
    Human chemotactic cytokine 失效
    人类趋化细胞因子

    公开(公告)号：US20090110659A1

    公开(公告)日：2009-04-30

    申请号：US12221458

    申请日：2008-08-01

    申请人： Paul D. Ponath ,  Shixin Qin ,  Douglas J. Ringler ,  Walter Newman ,  Charles Mackay

    发明人： Paul D. Ponath ,  Shixin Qin ,  Douglas J. Ringler ,  Walter Newman ,  Charles Mackay

    IPC分类号： A61K38/19 ,  C07H21/04 ,  C12N15/64 ,  C12N1/21 ,  C12N1/15 ,  A61P35/00 ,  C07K14/00 ,  C12P21/00 ,  G01N33/53

    CPC分类号： C07K16/24 ,  A61K38/00 ,  A61K47/642 ,  C07K14/523 ,  C07K14/7158 ,  C07K2317/76 ,  C07K2319/00

    摘要： The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.

    摘要翻译： 本发明涉及编码人类趋化性细胞因子（命名为人类嗜酸细胞活化趋化因子）的分离和/或重组核酸，以及包含合成多肽的分离和/或重组人类嗜酸细胞活化趋化因子蛋白或多肽。 本发明还涉及重组核酸构建体，其包含编码人类嗜酸细胞活化趋化因子，其部分或变体的核酸; 包含可用于生产重组人类嗜酸性粒细胞趋化因子的这种构建体的宿主细胞; 以及可用于体外方法，诊断和/或治疗的与人嗜酸细胞活化趋化因子反应的抗体。 还提供了使用嗜酸细胞活化趋化因子蛋白质的方法，例如将嗜酸性粒细胞募集到特定部位或用于治疗过敏性病症。 人类嗜酸性粒细胞趋化因子可用于鉴定可用于选择性调节白细胞功能，炎性和自身免疫疾病或感染的人类嗜酸细胞活化趋化因子的抑制剂（例如拮抗剂）或启动子（激动剂）。